Drug intelligence / Profile preview

HCVIVA

Development stage: Preclinical
Lead developer: AJ Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Parenteral

Overview

HCVIVA is a research-stage vaccine candidate currently in preclinical development for the prevention and treatment of chronic Hepatitis C virus (HCV) infection. The project is a collaborative effort between **AJ Vaccines**, serving as the commercial partner, and academic researchers led by Professor Judith Gottwein at **Hvidovre Hospital**. Funded by the Innovation Fund Denmark, the program aims to develop the first effective vaccine against HCV, a virus for which no vaccine currently exists despite the availability of curative direct-acting antivirals. As of mid-2025, the project is in the research phase with a projected timeline to enter human clinical trials within four to six years.

Other names: HCV vaccineHepatitis C vaccine

Targets

HCV E2 (Hepatitis C virus envelope glycoprotein E2)

Beyond the preview

Go deeper on HCVIVA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCVIVA.

Explore the full profile